|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hsu WH, Yang JC, Mok TS and Loong HH:
Overview of current systemic management of EGFR-mutant NSCLC. Ann
Oncol. 29 (Suppl_1):i3–i9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan J, Fong T, Xia Z, Zhang J and Luo P:
The efficacy and safety of ALK inhibitors in the treatment of
ALK-positive non-small cell lung cancer: A network meta-analysis.
Cancer Med. 7:4993–5005. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mantovani A, Marchesl F, Malesci A, Laghi
L and Allavena P: Tumor-associated macrophages as treatment targets
in oncololy. Nat Rev Clin Oncol. 14:399–416. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis CE and Pollard JW: Distinct role of
macrophages in different tumor microenvironments. Cancer Res.
66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Astekar M, Metqud R, Sharma A and Soni A:
Hidden keys in stroma: Unlocking the tumor progression. J Oral
Macxilofac Pathol. 17:82–88. 2013. View Article : Google Scholar
|
|
11
|
Mei J, Xiao Z, Guo C, Pu Q, Ma L, Liu C,
Lin F, Liao H, You Z and Liu L: Prognostic impact of
tumor-associated macrophage infiltration in non-small cell lung
cancer: A systemic review and meta-analysis. Oncotarget.
7:34217–34228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu P, Wu D, Zhao L, Huang L, Chen G, Shen
G, Huang J and Chai Y: Inverse role of distinct subsets and
distribution of macrophage in lung cancer prognosis: A
meta-analysis. Oncotarget. 7:40451–40460. 2016.PubMed/NCBI
|
|
13
|
Ong SM, Tan YC, Beretta O, Jiang D, Yeap
WH, Tai JJ, Wong WC, Yang H, Schwarz H, Lim KH, et al: Macrophages
in human colorectal cancer are pro-inflammatory and prime T cells
towards an anti-tumour type-1 inflammatory response. Eur J Immunol.
42:89–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Medrek C, Ponten F, Jirstrom K and
Leandersson K: The presence of tumor associated macrophages in
tumor stroma as a prognostic marker for breast cancer patients. BMC
Cancer. 12:3062012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Welsh TJ, Green RH, Richardson D, Waller
DA, O'Byrne KJ and Bradding P: Macrophage and mast-cell invasion of
tumor cell islets confers a marked survival advantage in
non-small-cell lung cancer. J Clin Oncol. 23:8959–8967. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DW, Min HS, Lee KH, Kim YJ, Oh DY,
Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, et al: High tumour islet
macrophage infiltration correlates with improved patient survival
but not with EGFR mutations, gene copy number or protein expression
in resected non-small cell lung cancer. Br J Cancer. 98:1118–1124.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawai O, Ishii G, Kubota K, Murata Y,
Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al:
Predominant infiltration of macrophages and CD8(+) T cells in
cancer nests is a significant predictor of survival in stage IV
nonsmall cell lung cancer. Cancer. 113:1387–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S,
Ma J, Ma L and You Z: The number and microlocalization of
tumor-associated immune cells are associated with patient's
survival time in non-small cell lung cancer. BMC Cancer.
10:2202010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng PH, Yu CT, Wu CY, Lee MJ, Lee WH,
Wang LS, Lin SM, Fu JF, Lee KY and Yen TH: Tumor-associated
macrophages in stage IIIA pN2 non-small cell lung cancer after
neoadjuvant chemotherapy and surgery. Am J Trans Res. 6:593–603.
2014.
|
|
20
|
Jackute J, Zemaitis M, Pranys D,
Sitkauskiene B, Miliauskas S, Vaitkiene S and Sakalauskas R:
Distribution of M1 and M2 macrophages in tumor islets and stroma in
relation to prognosis of non-small cell lung cancer. BMC Immunol.
19:32018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Dalen FJ, van Stevendaal MHME,
Fennemann FL, Verdoes M and Ilina O: Molecular repolarisation of
tumour-associated macrophages. Molecules. 24:E92018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT,
Kuo ML, Lee YC and Yang PC: Up-regulation of tumor interleukin-8
expression by infiltrating macrophages: Its correlation with tumor
angiogenesis and patient survival in non-small cell lung cancer.
Clin Cancer Res. 9:729–737. 2003.PubMed/NCBI
|
|
23
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma J, Liu L, Che G, Yu N, Dai F and You Z:
The M1 form of tumor-associated macrophages in non-small cell lung
cancer is positively associated with survival time. BMC Cancer.
10:1122010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung FT, Lee KY, Wang CW, Heh CC, Chan
YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, et al:
Tumor-associated macrophages correlate with response to epidermal
growth factor receptor-tyrosine kinase inhibitors in advanced
non-small cell lung cancer. Int J Cancer. 131:E227–E235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Amin MB, Edge S and Greene F: AJCC Cancer
Staging Manual8th. Springer; New York, NY, USA: 2017
|
|
27
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart4th. International Agency for Research on
Cancer; Lyon, France: 2015
|
|
28
|
Li Z, Maeda D, Yoshida M, Umakoshi M,
Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al:
The intratumoral distribution influences the prognostic impact of
CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scagliotti GV, Micela M, Gubetta L,
Leonardo E, Cappia S, Borasio P and Pozzi E: Prognostic
significance of Ki67 labelling in resected non small cell lung
cancer. Eur J Cancer 29A. 363–365. 1993. View Article : Google Scholar
|
|
30
|
Siemes C, Visser LE, Coebergh JW, Splinter
TA, Witteman JC, Uitterlinden AG, Hofman A, Pols HA and Stricker
BH: C-reactive protein levels, variation in the C-reactive protein
gene, and cancer risk: The Rotterdam Study. J Clin Oncol.
24:5216–5222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Allin KH, Bojesen SE and Nordestgaard BG:
Baseline C-reactive protein is associated with incident cancer and
survival in patients with cancer. J Clin Oncol. 27:2217–2224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carus A, Ladekarl M, Hager H, Pilegaard H,
Nielsen PS and Donskov F: Tumor-associated neutrophils and
macrophages in non-small cell lung cancer: No immediate impact on
patient outcome. Lung Cancer. 81:130–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lopez-Pastorini A, Riedel R, Koryllos A,
Beckers F, Ludwig C and Stoelben E: The impact of preoperative
elevated serum C-reactive protein on postoperative morbidity and
mortality after anatomic resection of lung cancer. Lung Cancer.
109:68–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leuzzi G, Galeone C, Gisabella M, Duranti
L, Taverna F, Suatoni P, Morelli D and Pastorino U: Baseline
C-reactive protein level predicts survival of early-stage lung
cancer: Evidence from a systematic review and meta-analysis.
Tumori. 102:441–449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kameda K, Eguchi T, Lu S, Qu Y, Tan KS,
Kadota K, Adusumilli PS and Travis WD: Implications of the eighth
edition of the TNM proposal: Invasive versus total tumor size for
the T descriptor in pathologic stage I–IIA lung adenocarcinoma. J
Thorac Oncol. 13:1919–1929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohtaki Y, Ishii G, Nagai K, Ashimine S,
Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I and Ochiai
A: Stromal macrophage expressing CD204 is associated with tumor
aggressiveness in lung adenocarcinoma. J Thorac Oncol. 5:1507–1515.
2010. View Article : Google Scholar : PubMed/NCBI
|
